-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:我们根据2026年1.2亿美元的预期市盈率(P/EBITDA)计算,将目标股价上调1美元至30美元,该预期市盈率为31.3倍,与三年预期总企业价值/息税折旧摊销前利润(TEV/EBITDA)平均值一致。我们认为,门店增长空间和智能眼镜的潜力足以抵消消费者折扣的影响,因此我们上调市盈率是合理的。我们将2026年每股收益(EPS)预期上调0.07美元至0.50美元,并将2027年每股收益预期上调0.02美元至0.65美元。我们预测2026年和2027年营收分别为9.75亿美元和11亿美元。鉴于今日股价已大幅上涨,我们认为股价上涨空间可能仅限于我们认为的公允价值,即我们的目标价。我们认为,鉴于我们采用了市盈率/息税折旧摊销前利润倍数(P/EBITDA),WRBY 的股权风险溢价不应更高。我们认为,2026-2027 年的营收同比增长并不足以支撑更高的估值倍数。尽管如此,WRBY 在竞争激烈的零售眼镜市场拥有成熟的商业模式。我们怀疑智能眼镜的创新能否在未来一年显著提升净销售额。
Related Articles
Galloper Gold to Begin 2026 Drilling Program at the Glover Island Property
Galloper Gold (BOOM.CN) on Thursday said it plans to begin a 2026 drilling program at Glover Island targeting new high-grade gold targets in the Lunch Pond South Extension (LPSE) gold deposit.The company also plans regional exploration drilling, particularly at Lucky Smoke.An updated geological modelling and engineering exercise resulted in the recently released and increased LPSE Mineral Resource Estimate (MRE), said the company and added that the 2026 drilling program will follow-up and build on this "momentum."The 2026 drilling program is expected to include up to 7,000 meters of diamond drilling in over 25 boreholes. Drilling will target along-strike and down-dip continuity of the LPSE and Lucky Smoke gold deposits within the Kettle Pond formation, the company added."Galloper Gold Corp. has been comprehensively evaluating the Kettle Pond Formation gold mineralized trend with historical data, and, as a result of this, we have recently released an updated MRE for the LPSE deposit," said chief executive Hratch Jabrayan. "This effort has resulted in a new understanding of the geological architecture of the property and has built targeting for additional gold mineralization intercepts."Shares of the company were last seen unchanged at $0.10 on the Canadian Securities Exchange.
United Therapeutics Growth Outlook Remains Supported by Tyvaso, Ralinepag, RBC Says
United Therapeutics (UTHR) still has a stronger long-term growth path despite a soft Q1, helped by Tyvaso durability, possible idiopathic pulmonary fibrosis expansion, TreSMI filing plans, and future upside from ralinepag, RBC Capital Markets said in a note emailed Thursday.The investment firm said Tyvaso revenue missed estimates in Q1, but the firm expects the franchise to return to growth after weather issues and specialty pharmacy delays subside.IPF could become the company's next major growth driver, with a supplemental application still planned for this summer and other faster approval paths under review, RBC said.TreSMI remains on track for a US Food and Drug Administration filing in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease by year's end, which could help United Therapeutics defend its position in inhaled treprostinil, according to the note.Ralinepag Dry Powder Inhalation could add longer-term upside because once daily dosing may help the company compete better in pulmonary hypertension and related lung disease markets, RBC added.RBC lowered its price target for United Therapeutics to $701 from $707 while keeping its outperform rating.Price: $576.22, Change: $-20.55, Percent Change: -3.44%
Klaviyo to Bring Agentic Marketing Workflows to Anthropic's Claude
Klaviyo (KVYO) said Thursday it has expanded its integration with Anthropic to provide new agentic marketing workflows to the Claude AI model.Customers will be able to securely access and generate outputs from their customer and performance data through the connection of Klaviyo's Model Context Protocol server across Claude's products, according to a statement.Price: $15.84, Change: $+0.03, Percent Change: +0.18%